• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PPD Projects 12% Growth in 2009

PPD Projects 12% Growth in 2009

January 15, 2009
CenterWatch Staff

Wilmington, N.C.-based PPD expects net revenue for 2009 to be in the range of $1.595 to $1.670 billion, a 12% increase over the CRO’s 2008 net revenue forecast. The company projects diluted earnings per share (EPS) for the full year 2009 will be in the range of $1.97 to $2.05, an 18% increase over its full year 2008 EPS forecast.

In October, based on Q3 financial results, the company lowered its full year 2008 revenue projection to between $1.47 billion and $1.49 billion from $1.54 billion to $1.59 billion as a result of an FDA delay in approving diabetes drug alogliptin.

“Our 2009 financial guidance demonstrates our confidence in the core development business, and we plan to continue to focus our efforts on sales execution and operational excellence throughout the year,” PPD CEO Fred Eshelman said in a company release.

PPD announced earlier this week that it has entered into a strategic alliance with World Health Information Science Consultants in order to expand its post-approval drug safety expertise in epidemiology, risk management and pharmacovigilance.

Last week, the company announced a strategic collaboration with Merck that will significantly expand PPD’s global central laboratory business.

“While we enter 2009 facing the stiff headwinds of a global recession, which may affect R&D spending, it is clear that biopharmaceutical companies see strategic partnering as an imperative,” PPD chief operating officer William Sharbaugh told investors in a conference call this morning.

PPD’s shares were down 1.69% to $1.16 in early morning trading.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing